Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP

M

Midway Specialty Care Center

Status

Enrolling

Conditions

Hiv

Treatments

Drug: Cabotegravir Injection [Apretude]

Study type

Observational

Funder types

Other

Identifiers

NCT06145854
2022-01

Details and patient eligibility

About

Oral PrEP regimens (FTC/TDF have been the mainstay of HIV prevention however patients now have more options for HIV prevention. In addition to oral PrEP regimens, the FDA approved the use of long acting Cabotegravir (CAB-LA) as the first long-acting medication for HIV prevention. This study will evaluate real world clinical outcomes of cisgender female patients who start CAB-LA for PrEP.

Enrollment

100 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Cisgender females, ages 18 years and older
  • Negative HIV test at baseline
  • Negative Pregnancy test at baseline
  • Weigh at least 35 kilograms
  • Already Prescribed CAB-LA (Apretude)

Exclusion criteria

  • Transgender females or males
  • Cisgender males
  • Cisgender female who is actively breastfeeding
  • Severe hepatotoxicity
  • Evidence of Hepatitis B Infection
  • History or presence of allergies to cabotegravir or its components

Trial design

100 participants in 1 patient group

Cisgender Females
Treatment:
Drug: Cabotegravir Injection [Apretude]

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems